MRSA Dermal Decolonization Study 2 - MDDS2

BioPlx Microbiomics Inc0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1) Provision of signed and dated informed consent form.
•2) Stated willingness to comply with all study procedures and availability for the duration of the study.
•3) History of positive Staphylococcus aureus bacteremia as confirmed by treating physician.
•4) Positive methicillin-resistant Staphylococcus aureus CHROMagar plate from screening nasal swab.
•5) Agreement to adhere to the avoidance of antibiotic use unless instructed by a physician and the use of antimicrobial soaps and skin antiseptic applications throughout study duration.

•1) Current use of oral, intravenous, or topical antibiotics.
•2) History of autoimmune disease, immunosuppressive conditions or therapy.
•3) Active diagnosis of cancer.
•4) Active diagnosis of infection.
•5) History of diabetes mellitus with HgbA1C > 6.5.
•6) Planned pregnancy during the study or current pregnancy.
•7) Febrile illness within 1 week of enrollment.
•8) Receipt of a live virus vaccine within the 2 months prior to enrollment.
•9) Treatment with another investigational drug or other intervention within 3 months of enrollment.
•10) Chronic skin conditions such as eczema.

发起方

BioPlx Microbiomics Inc